US Patent Issued to Regeneron Pharmaceuticals on Oct. 14 for "Anti-FC epsilon-R1 Alpha (FCepsilonR1Alpha) antibodies, bispecific antigen-binding molecules that bind FCepsilonR1Alpha and CD3, and uses thereof" (New York Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,797, issued on Oct. 14, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Anti-FC epsilon-R1 Alpha (FCepsilonR1Alpha) antibodies, bispecific antigen-binding molecules that bind FCepsilonR1Alpha and CD3, and uses thereof" was invented by Jamie M. Orengo (Cortlandt Manor, N.Y.), Andre Limnander (New York), Jee H. Kim (Ardsley, N.Y.) and Andrew J. Murphy (Tarrytown, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides novel full-length human antibodies that bind to human Fc epsilon-R1 alpha (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both ...